Certara thought leaders will present pharmacometric workshops, talks and posters at this year’s conference
PRINCETON, NJ – Oct. 21, 2016 –Certara®, the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, today announced it will be participating in 19 sessions at the Seventh American Conference on Pharmacometrics (ACoP7). This year’s conference is being held from Oct. 23-26 in Bellevue, Washington.
“Pharmacometrics now influences the most important decisions made at every stage of the drug development process from discovery through to patient care. It has been embraced by sponsors and global regulatory agencies alike. They are using modeling and simulation to examine potential drug-drug interactions; determine drug doses for vulnerable populations such as pediatric and elderly patients, pregnant women, and patients with impaired organ function; and inform drug labels,” said Certara CEO Edmundo Muniz, MD, PhD. “As pharmacometrics grows in importance, so does ACoP. We are proud to play such a significant role at this year’s conference.”
Certara will participate in the following sessions at ACoP7:
Saturday, Oct. 22
Pre-meeting Workshop
8:00 a.m.-5:00 p.m.
- Bridging PBPK with PopPK for Pediatrics – Khaled Abduljalil
Sunday, Oct. 23
Pre-meeting Workshop
8:00 a.m.-5:00 p.m.
- Physiological Modeling of Therapeutic Proteins and Antibody-drug Conjugates – Iain Gardner
Posters
12:00-1:15 p.m.
- S-06: Raltegravir PK in Neonates – An Adaptive Trial Design to Define an Appropriate Regimen for Neonates from Birth to Six Weeks of Age – Jos Lommerse
- S-11: Raltegravir PK in Neonates – Modeling Rising and Declining PK Profiles of Newborns Exposed to Raltegravir In-utero – Jos Lommerse
- S-12: Does Birth Have an Effect on UGT2B7 Activity in Neonates? – Farzaneh Salem
Monday, Oct. 24
Posters
7:30-9:30 a.m.
- M-55: An Efficient Language for Model-based Trial Simulations – Shuhua Hu
- M-56: Simulation of Complex Population PK/PD Models with Adaptive Dosing Regimens – Shuhua Hu
- M-63: Efficacy Exposure-response Analysis for Declatasvir/Asunaprevir/Beclabuvir Regimen in Hepatitis C Virus Infected Subjects – Michelle Green (contributing author)
Talks
9:45-11:30 a.m.
- Session 1: Bridging Proof of Mechanism to Efficacy: A Systems Pharmacology Approach – Piet van der Graaf
2:15-3:45 p.m.
- Session 2b: Pre-diction vs Post-diction: Fusion of PBPK and PopPK – How and Why? – Amin Rostami
Tuesday, Oct. 25
Posters
7:30-9:00 a.m.
- T-02: Exposure-response Analyses of C1 Esterase Inhibitor in Adult and Pediatric Patients for the Prevention and Treatment of Hereditary Angioedema Attacks – Yi Wang, Grygoriy Vasilinin, Jennifer Schwartz, Patrick Martin, and JF Marier
- T-12: Does Birth Have an Effect on UGT2B7 Activity in Neonates? – Farzaneh Salem
- T-13: Performance and Scalability of Parallel Computing in Biosimulation/Modeling Platforms for Pharmacometric Solutions – Kairui Feng
- T-26: Population PK and Exposure-response Analyses of Icatibant in Pediatric Patients for the Treatment of Hereditary Angioedema – Yi Wang, Claudia Jomphe, Jennifer Schranz, Patrick Martin, and JF Marier
- T-33: Raltegravir PK in Neonates – An Adaptive Trial Design to Define an Appropriate Regimen for Neonates from Birth to Six Weeks of Age – Jos Lommerse
- T-34: Raltegravir PK in Neonates – Modeling Rising and Declining PK Profiles of Newborns Exposed to Raltegravir In-utero – Jos Lommerse
- T-66: Application of Population Pharmacokinetics/Pharmacodynamics (PopPK-PD) for Selection of Optimal Dose of Amiselimod – Mathilde Marchand (contributing author)
- T-70: Population Pharmacokinetics for Atezolizumab in Cancer Patients – Mathilde Marchand
Talks
10:30 a.m.-12:00 p.m.
- Session 4c: Model-based Analysis of Biopharmaceutical Experiments to Improve Mechanistic PBPK Modeling – Shriram M Pathak
3:00-5:00 p.m.
- Session 5b: Pediatric PBPK/PD Modeling Clinical and Drug Development Applications: Case Examples – Trevor Johnson
Wednesday, Oct. 26
Posters
7:30-9:30 a.m.
- W-37: Population PK Analysis of C1 Esterase Inhibitor in Adult and Pediatric Patients for the Prevention and Treatment of Hereditary Angioedema Attacks – Yi Wang, Grygoriy Vasilinin, Jennifer Schwartz, Patrick Martin, and JF Marier
- W-67: Empowering Nonmodelers to Query and Use Your Models – Samer Mouksassi
About Certara
Certara is a leading decision support technology and consulting organization committed to optimizing drug development and improving health outcomes. Certara’s solutions, which span drug discovery through patient care, use the most scientifically-advanced modeling and simulation technologies and regulatory strategies to increase the probability of regulatory and commercial success. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions, and key regulatory agencies. For more information, visit www.certara.com.
Certara Contact:
Ellen Leinfuss, 609-216-9586
Chief Marketing Officer
Media Contact:
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions
lisa@ranahealth.com